PRRT2 and hepatocellular carcinoma: A specific PKCα substrate or pan-PKC-substrate antibodies showed strong signal only in M-HCC cells suggesting PKCα is the candidate kinase that is inhibited by PKC inhibitors (Fig. 6a)26,27.